Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes

Current Neurovascular Research

Volumn 8, Issue 4, 2011, Pages 294-304

  Negi, Geeta ^a   Kumar, Ashutosh ^a   Sharma, Shyam S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetic neuropathy; Inflammation; NF B; Nrf2; Oxidative stress; Sulforaphane

Indexed keywords

CYCLOOXYGENASE 2; GLUCOSE; HEME OXYGENASE 1; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MALONALDEHYDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); STREPTOZOCIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCIATIC NERVE;

EID: 82155197554     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720211798120972     Document Type: Article

References (55)

1. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009; 47 (9):1304-09.
2. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005; 7 (3-4):385-94. (Pubitemid 40279806)
3. Li W, Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 2009; 48 (2):91-104.
4. Wakabayashi N, Slocum SL, Skoko JJ, et al. When Nrf2 Talks, Who's Listening? Antioxid Redox Signal 2010; 13:1649-63.
5. Innamorato NG, Rojo AI, Garcia-Yague AJ, et al. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 2008; 181 (1):680-89.
6. Negi G, Kumar A , Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κ B and Nrf2 cascades. J Pineal Res 2011; 50 (2):124-31.
7. Tanaka N, Ikeda Y, Ohta Y, et al. Expression of Keap1-Nrf2 system and antioxidative proteins in mouse brain after transient middle cerebral artery occlusion. Brain Res 2010; 1370246-53.
8. Ungvari Z, Bagi Z, Feher A, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010; 299 (1):H18-24.
9. Zhao J, Yu S, Wu J, et al. Curcumin and Nrf2 Protect against Neuronal Oxidative Stress and Delayed Death Caused by Oxygen and Glucose Deprivation. Curr Neurovasc Res 2011. In press
10. Negi G, Kumar A, Joshi RP , Sharma SS. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: Old perspective with a new angle. Biochem Biophys Res Commun 2011; 408 (1):1-5.
11. Karin M, Yamamoto Y, Wang QM. The IKK NF-κ B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3 (1):17-26. (Pubitemid 38088695)
12. Baker RG, Hayden MS, Ghosh S. NF-κ B, inflammation, and metabolic disease. Cell Metab 2011; 13 (1):11-22.
13. Chen YW, Chenier I, Chang SY, et al. High glucose promotes nascent nephron apoptosis via NF-κ B and p53 pathways. Am J Physiol Renal Physiol 2011; 300 (1):F147-56.
14. Choudhary S, Sinha S, Zhao Y, et al. NF-κB-Inducing Kinase (NIK) Mediates Skeletal Muscle Insulin Resistance: Blockade by Adiponectin. Endocrinology 2011; 152 (10):3622-27.
15. Kumar A, Negi G, Sharma SS. JSH-23 targets nuclear factor kappa B (NF-κ B) and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab 2011; 13(8):750-58
16. Kumar A, Sharma SS. NF-κ B inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 394 (2):360-65.
17. Song MY, Kim EK, Moon WS, et al. Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-κ B pathway. Toxicol Appl Pharmacol 2009; 235 (1):57-67.
18. Mao AJ, Bechberger J, Lidington D, et al. Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43. J Biol Chem 2000; 275 (44):34407-14.
19. Kumar A, Kaundal RK, Iyer S, Sharma SS. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007; 80 (13):1236-44. (Pubitemid 46329013)
20. Sharma SS, Kumar A, Arora M, Kaundal RK. Neuroprotective potential of combination of resveratrol and 4-amino 1,8 naphthalimide in experimental diabetic neuropathy: Focus on functional, sensorimotor and biochemical changes. Free Radical Research 2009; 43 (4):400-08.
21. Negi G, Kumar A, Kaundal RK, et al. Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010; 58 (3):585-92.
22. Negi G, Kumar A, Sharma SS. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem Biophys Res Commun 2010; 391 (1):102-06.
23. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95 (2):351-58. (Pubitemid 9194347)
24. Obrosova IG, Li F, Abatan OI , et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004; 53 (3):711-20. (Pubitemid 38270641)
25. Mc Mahon M, Itoh K, Yamamoto M, et al. The Cap and Collar Basic Leucine Zipper Transcription Factor Nrf2 (NF-E2 p45-related Factor 2) Controls Both Constitutive and Inducible Expression of Intestinal Detoxification and Glutathione Biosynthetic Enzymes. Cancer Res 2001; 61 (8):3299-307. (Pubitemid 32695017)
26. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010; 13 (11):1665-78.
27. Jung KA, Kwak MK. The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 2010; 15 (10):7266-91.
28. Lau A, Villeneuve NF, Sun Z , et al. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58 (5-6):262-70.
29. Tkachev VO, Menshchikova EB, Zenkov NK. Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (Mosc) 2011; 76 (4):407-22.
30. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010; 501 (1):116-23.
31. Xue M, Qian Q, Adaikalakoteswari A, et al. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008; 57 (10):2809-17.
32. Yoon HY, Kang NI, Lee HK, et al. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 2008; 75 (11):2214-23.
33. Zhao J, Kobori N, Aronowski J, Dash PK. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 2006; 393 (2-3):108-12. (Pubitemid 41821089)
34. Li M, Kim DH, Tsenovoy PL, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57 (6):1526-35.
35. Nicolai A, Li M, Kim DH, et al. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity- induced diabetic rats. Hypertension 2009; 53 (3):508-15.
36. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 2000; 12 (1-4):5-11. (Pubitemid 32107378)
37. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236 (2):313-22. (Pubitemid 27373291)
38. Mc Mahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003; 278 (24):21592-600. (Pubitemid 36792558)
39. Ghosh S, May MJ, Kopp EB. NF-κ B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225-60. (Pubitemid 28183365)
40. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF- kappa B activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010; 1799 (10-12):775-87.
41. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-k B): an emerging theme in anti-inflammatory therapies. Mol Interv 2002; 2 (1):22-35.
42. Anest V, Hanson JL, Cogswell PC, et al. A nucleosomal function for Ikappa B kinase-alpha in NF-κ B-dependent gene expression. Nature 2003; 423 (6940):659-63. (Pubitemid 36713228)
43. Yamamoto Y, Verma UN, Prajapati S, et al. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003; 423 (6940):655-59. (Pubitemid 36713227)
44. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 1998; 9 (3-4):259-75. (Pubitemid 29019710)
45. Lisak RP, Bealmear B, Benjamins JA, Skoff AM. Interferon- gamma, tumor necrosis factor-alpha, and transforming growth factor-beta inhibit cyclic AMP-induced Schwann cell differentiation. Glia 2001; 36 (3):354-63. (Pubitemid 34010063)
46. Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diab Res 2003; 4 (4):303-12. (Pubitemid 38035569)
47. Bolin LM, Verity AN, Silver JE, et al. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochem 1995; 64 (2):850-58.
48. Skoff AM, Lisak RP, Bealmear B, Benjamins JA. TNF-alpha and TGF-beta act synergistically to kill Schwann cells. J Neurosci Res 1998; 53 (6):747-56. (Pubitemid 28423882)
49. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and Diabetes. Diabetes 2005; 54 (suppl 2):S114-S24.
50. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 2003; 111 (2):163-69. (Pubitemid 36105911)
51. Gilad E, Wong HR, Zingarelli B, et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFκB activation. FASEB J 1998; 12 (9):685-93. (Pubitemid 28247147)
52. Matsunaga A, Kawamoto M, Shiraishi S, et al. Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 2007; 554 (1):12-17. (Pubitemid 44820041)
53. Lin W, Wu RT, Wu T, et al. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol 2008; 76 (8):967-73.
54. Heiss E, Herhaus C, Klimo K, et al. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276 (34):32008-15.
55. Luedde T, Assmus U, Wustefeld T, et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005; 115 (4):849-59. (Pubitemid 40489389)